These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34433423)

  • 1. Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats.
    Nesbitt DJ; Jin DP; Hogan JW; Yang J; Chen H; Chan PA; Simon MJ; Vargas M; King E; Huard RC; Bandy U; Hillyer CD; Luchsinger LL
    BMC Infect Dis; 2021 Aug; 21(1):871. PubMed ID: 34433423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and "Reopening".
    Jin DK; Nesbitt DJ; Yang J; Chen H; Horowitz J; Jones M; Vandergaast R; Carey T; Reiter S; Russell SJ; Kyratsous C; Hooper A; Hamilton J; Ferreira M; Deng S; Straus D; Baras A; Hillyer CD; Luchsinger LL
    PLoS One; 2021; 16(4):e0250319. PubMed ID: 33909646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
    Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
    J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays.
    Tuite AR; Fisman D; Abe KT; Rathod B; Pasculescu A; Colwill K; Gingras AC; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2022 Feb; 10(1):e0256321. PubMed ID: 35196819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
    Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
    Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study.
    Pallett SJC; Rayment M; Patel A; Fitzgerald-Smith SAM; Denny SJ; Charani E; Mai AL; Gilmour KC; Hatcher J; Scott C; Randell P; Mughal N; Jones R; Moore LSP; Davies GW
    Lancet Respir Med; 2020 Sep; 8(9):885-894. PubMed ID: 32717210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors.
    Erikstrup C; Hother CE; Pedersen OBV; Mølbak K; Skov RL; Holm DK; Sækmose SG; Nilsson AC; Brooks PT; Boldsen JK; Mikkelsen C; Gybel-Brask M; Sørensen E; Dinh KM; Mikkelsen S; Møller BK; Haunstrup T; Harritshøj L; Jensen BA; Hjalgrim H; Lillevang ST; Ullum H
    Clin Infect Dis; 2021 Jan; 72(2):249-253. PubMed ID: 33501969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.
    Barchuk A; Skougarevskiy D; Kouprianov A; Shirokov D; Dudkina O; Tursun-Zade R; Sergeeva M; Tychkova V; Komissarov A; Zheltukhina A; Lioznov D; Isaev A; Pomerantseva E; Zhikrivetskaya S; Sofronova Y; Blagodatskikh K; Titaev K; Barabanova L; Danilenko D
    PLoS One; 2022; 17(6):e0266945. PubMed ID: 35704649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
    Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
    Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned.
    Poljak M; Oštrbenk Valenčak A; Štrumbelj E; Maver Vodičar P; Vehovar V; Resman Rus K; Korva M; Knap N; Seme K; Petrovec M; Zupan B; Demšar J; Kurdija S; Avšič Županc T
    Clin Microbiol Infect; 2021 Jul; 27(7):1039.e1-1039.e7. PubMed ID: 33838303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 antibody kinetics in blood donors with a previously positive SARS-CoV-2 antibody test within a seroprevalence survey.
    Levring MB; Holm DK; Nilsson AC; Bauer JM; Jensen IS; Davidsen JR; Rasmussen LD; Sprogøe U; Lillevang ST
    J Med Virol; 2022 Apr; 94(4):1711-1716. PubMed ID: 34845745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts.
    Bortz RH; Florez C; Laudermilch E; Wirchnianski AS; Lasso G; Malonis RJ; Georgiev GI; Vergnolle O; Herrera NG; Morano NC; Campbell ST; Orner EP; Mengotto A; Dieterle ME; Fels JM; Haslwanter D; Jangra RK; Celikgil A; Kimmel D; Lee JH; Mariano MC; Nakouzi A; Quiroz J; Rivera J; Szymczak WA; Tong K; Barnhill J; Forsell MNE; Ahlm C; Stein DT; Pirofski LA; Goldstein DY; Garforth SJ; Almo SC; Daily JP; Prystowsky MB; Faix JD; Fox AS; Weiss LM; Lai JR; Chandran K
    mSphere; 2021 Apr; 6(2):. PubMed ID: 33883259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard.
    Saeed S; O'Brien SF; Abe K; Yi QL; Rathod B; Wang J; Fazel-Zarandi M; Tuite A; Fisman D; Wood H; Colwill K; Gingras AC; Drews SJ
    PLoS One; 2021; 16(9):e0257743. PubMed ID: 34555095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological Tools in Challenging Settings.
    Saluzzo F; Mantegani P; Poletti De Chaurand V; Quaresima V; Cugnata F; Di Serio C; Macé A; De Vos M; Sacks JA; Cirillo DM
    Microbiol Spectr; 2021 Oct; 9(2):e0025021. PubMed ID: 34549999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample.
    Chan PA; King E; Xu Y; Goedel W; Lasher L; Vargas M; Brindamour K; Huard R; Clyne A; McDonald J; Bandy U; Yokum D; Rogers ML; Chambers L; Napoleon SC; Alexander-Scott N; Hogan JW
    Am J Public Health; 2021 Apr; 111(4):700-703. PubMed ID: 33600249
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia.
    Barchuk A; Shirokov D; Sergeeva M; Tursun Zade R; Dudkina O; Tychkova V; Barabanova L; Skougarevskiy D; Danilenko D
    J Med Virol; 2021 Oct; 93(10):5846-5852. PubMed ID: 34081328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era.
    Reedman CN; Drews SJ; Yi QL; Pambrun C; O'Brien SF
    Microbiol Spectr; 2022 Apr; 10(2):e0033922. PubMed ID: 35412385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program.
    Stone M; Di Germanio C; Wright DJ; Sulaeman H; Dave H; Fink RV; Notari EP; Green V; Strauss D; Kessler D; Destree M; Saa P; Williamson PC; Simmons G; Stramer SL; Opsomer J; Jones JM; Kleinman S; Busch MP;
    Clin Infect Dis; 2022 Mar; 74(5):871-881. PubMed ID: 34111244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.